First patient enrolled in merit medical's multicenter observational study to evaluate the use of embocube® embolization gelatin to control bleeding or hemorrhage

South jordan, utah, dec. 05, 2022 (globe newswire) -- merit medical systems, inc. (nasdaq: mmsi), a leading global manufacturer and marketer of healthcare technology, announced today the successful enrollment of the first patient in its prospective, observational study of embocube embolization gelatin used to control bleeding or hemorrhage.
MMSI Ratings Summary
MMSI Quant Ranking